Roche, PacBio to Develop NGS-based Clinical Dx in Potential $75M Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences today announced an agreement with Roche Diagnostics to develop diagnostic products based on PacBio's SMRT technology.

Including upfront, milestone, and supply payments, the deal is potentially worth more than $75 million to PacBio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.